SRx Health Solutions Fined by NYSE American for Share Issuance Violations

Event summary

  • SRx Health Solutions received a warning letter from NYSE American on February 18, 2026, for violating Sections 301 and 713 of the NYSE American LLC Company Guide.
  • The violations stemmed from the issuance of approximately 7.5 million shares of common stock between December 31, 2025, and January 23, 2026, upon conversion of Series A Convertible Preferred Stock.
  • The company failed to file an application for listing approval and obtain stockholder approval for the issuance that exceeded 20% of the common stock outstanding.
  • All Preferred Shares have been either converted into Common Stock or redeemed by February 20, 2026.

The big picture

SRx Health Solutions' violation highlights the critical importance of adhering to exchange listing requirements, particularly for companies engaging in significant share issuances. This incident underscores the regulatory scrutiny faced by publicly traded healthcare firms and the potential market repercussions of non-compliance.

What we're watching

Regulatory Compliance
How SRx Health Solutions will address the deficiencies in stockholder approval to avoid further regulatory actions.
Market Confidence
Whether the company can regain investor trust following the NYSE American's warning letter.
Operational Impact
The pace at which SRx Health Solutions can implement corrective measures to ensure compliance with NYSE American regulations.